Atlas Trials

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

Clinical trial NCT03634059 · UNKNOWN

Trial details

NCT number
NCT03634059
Sponsor
Hebei Medical University Fourth Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
NSCLC
Start date
2018-08-15
Primary completion
2019-08-15
Enrollment
80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.